Syndax Pharmaceuticals issues $2.25% convertible senior notes due 2031

Syndax Pharmaceuticals entered into an indenture agreement with U.S. Bank Trust Company for convertible senior notes with a 2.25% interest rate maturing in 2031. This debt offering provides capital financing for the biopharmaceutical company's operations and development initiatives.